Literature DB >> 27324144

Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction.

Sean van Diepen1,2,3, Wendimagegn G Alemayehu4, Yinggan Zheng4, Pierre Theroux5, L Kristin Newby6, Kenneth W Mahaffey7, Christopher B Granger5, Paul W Armstrong4,8.   

Abstract

Coronary plaque rupture mediating acute ST segment elevation myocardial infarction (STEMI) is associated with a systemic inflammatory response. Whether early temporal changes in inflammatory biomarkers are associated with angiographic and electrocardiographic markers of reperfusion and subsequent clinical outcomes is unclear. In the APEX-AMI biomarker substudy, 376 patients with STEMI had inflammatory biomarkers measured at the time of hospital presentation and 24 h later. The primary outcome was the 90-day composite of death, shock, or heart failure. Secondary reperfusion outcomes were (1) worst least residual ST segment elevation (ST-E: <1 mm, 1 to <2 mm, ≥2 mm) and (2) post-percutaneous coronary intervention (PCI) TIMI flow grade (0/1/2 vs 3) and TIMI myocardial perfusion grade (TMPG 0/1 vs 2/3). The 90-day incidence of death, shock or heart failure was 21.3 % in this cohort. Electrocardiographic reperfusion (worst residual ST-E <1 mm, 1 to <2 mm, ≥2 mm) was associated with differences in 24 h change in N-terminal proB-type natriuretic peptide (NT-proBNP) (1192.8, 1332.5, 1859.0 ng/mL; p = 0.043) and the pro-inflammatory cytokines Interleukin (IL)-6 (14.0, 13.6, 22.1 pg/mL; p = 0.016), IL-12 (-0.5, -0.9, -0.1 pg/mL; p = 0.013), and tumor necrosis factor α (TNFα) (1.0, 0.6, 3.6 pg/mL; p = 0.023). Angiographic reperfusion (TMPG 0/1 vs 2/3) was associated with changes in median NT-proBNP (2649.3, 1382.7 ng/mL; p = 0.002) and IL-6 (28.7, 15.1; p = 0.040). After adjustment for baseline covariates, the 24 h change in the pro-inflammatory cytokine TNFα [hazard ratio (HR) 0.49; 95 % CI 0.26-0.95; p = 0.035] and the anti-inflammatory cytokine IL 10 (HR 1.41; 95 % CI 1.06-1.87; p = 0.018) were independently associated with the primary composite outcome. Successful coronary reperfusion was associated with less systemic inflammatory response and greater temporal inflammatory changes were independently associated with higher 90-day composite of death, shock, or heart failure. These findings provide support for an association between success of reperfusion, an acute STEMI inflammatory response and subsequent clinical outcomes.

Entities:  

Keywords:  Electrocardiographic reperfusion; Inflammatory biomarkers; ST segment elevation myocardial infarction; TIMI flow grade; TIMI myocardial perfusion grade

Mesh:

Substances:

Year:  2016        PMID: 27324144     DOI: 10.1007/s11239-016-1390-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  41 in total

1.  Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

Authors:  Sean van Diepen; Matthew T Roe; Renato D Lopes; Amanda Stebbins; Stefan James; L Kristin Newby; David J Moliterno; Franz-Josef Neumann; Justin A Ezekowitz; Kenneth W Mahaffey; Judith S Hochman; Christian W Hamm; Paul W Armstrong; Pierre Theroux; Christopher B Granger
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

2.  Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome.

Authors:  Georgios K Chalikias; Dimitrios N Tziakas; Juan Carlos Kaski; Eleni I Hatzinikolaou; Dimitrios A Stakos; Ioannis K Tentes; Alexandros Kortsaris; Dimitrios I Hatseras
Journal:  Atherosclerosis       Date:  2005-02-26       Impact factor: 5.162

3.  Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

Authors:  Paul W Armstrong; Christopher B Granger; Peter X Adams; Christian Hamm; David Holmes; William W O'Neill; Thomas G Todaro; Alec Vahanian; Frans Van de Werf
Journal:  JAMA       Date:  2007-01-03       Impact factor: 56.272

4.  Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Janusz Szkodzinski; Bartosz Hudzik; Marcin Osuch; Wojciech Romanowski; Bozena Szygula-Jurkiewicz; Lech Polonski; Barbara Zubelewicz-Szkodzinska
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

5.  Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Stephan Fichtlscherer; Eric Boersma; Maarten L Simoons; Andreas M Zeiher
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

6.  Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats.

Authors:  Alexander Deten; Hans Christian Volz; Wilfried Briest; Heinz-Gerd Zimmer
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

7.  B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.

Authors:  Jessica L Mega; David A Morrow; James A De Lemos; Marc S Sabatine; Sabina A Murphy; Nader Rifai; C Michael Gibson; Elliott M Antman; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2004-07-21       Impact factor: 24.094

8.  ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Authors:  Christopher E Buller; Yuling Fu; Kenneth W Mahaffey; Thomas G Todaro; Peter Adams; Cynthia M Westerhout; Harvey D White; Arnoud W J van 't Hof; Frans J Van de Werf; Galen S Wagner; Christopher B Granger; Paul W Armstrong
Journal:  Circulation       Date:  2008-09-08       Impact factor: 29.690

9.  Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Authors:  Catherine Martel; Christopher B Granger; Marta Ghitescu; Amanda Stebbins; Annik Fortier; Paul W Armstrong; Arnaud Bonnefoy; Pierre Theroux
Journal:  Am Heart J       Date:  2012-06-15       Impact factor: 4.749

10.  Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

Authors:  Peter Damman; Marcel A M Beijk; Wichert J Kuijt; Niels J W Verouden; Nan van Geloven; José P S Henriques; Jan Baan; Marije M Vis; Martijn Meuwissen; Jan P van Straalen; Johan Fischer; Karel T Koch; Jan J Piek; Jan G P Tijssen; Robbert J de Winter
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

View more
  5 in total

Review 1.  Immunopathophysiology of trauma-related acute kidney injury.

Authors:  David A C Messerer; Rebecca Halbgebauer; Bo Nilsson; Hermann Pavenstädt; Peter Radermacher; Markus Huber-Lang
Journal:  Nat Rev Nephrol       Date:  2020-09-21       Impact factor: 28.314

2.  Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs.

Authors:  Pranitha Kamat; Stijn Vandenberghe; Stephan Christen; Anjan K Bongoni; Bernhard Meier; Robert Rieben; Ahmed A Khattab
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

3.  Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.

Authors:  Jay S Shavadia; Christopher B Granger; Wendimagegn Alemayehu; Cynthia M Westerhout; Thomas J Povsic; Sean Van Diepen; Christopher Defilippi; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2020-06-17       Impact factor: 5.501

4.  Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial.

Authors:  Gorav Batra; Henrik Renlund; Vijay Kunadian; Stefan K James; Robert F Storey; P Gabriel Steg; Hugo A Katus; Robert A Harrington; C Michael Gibson; Andrzej Budaj; Agneta Siegbahn; Lars Wallentin
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-06-07

5.  Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction.

Authors:  Hilde E Groot; Lawien Al Ali; Iwan C C van der Horst; Remco A J Schurer; Hindrik W van der Werf; Erik Lipsic; Dirk J van Veldhuisen; Jacco C Karper; Pim van der Harst
Journal:  Clin Res Cardiol       Date:  2018-10-26       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.